Sign in Register

Drug class

Adenosine

Adenosine is a specific active drug moiety and endogenous purine nucleoside rather than an independent therapeutic drug class; in regulatory and pharmacological classification systems such as the FDA Established Pharmacologic Class index, it is categorized as an adenosine receptor agonist and classified clinically among miscellaneous antiarrhythmics. Read more about Adenosine

12 drugs in this class 9 manufacturers

Related classes & indications

Calcium Channel BlockersCardiovascular & renal · 344 prescription drugs Angiotensin II Receptor Antagonists (ARBs)Cardiovascular & renal · 281 prescription drugs Paroxysmal Supraventricular TachycardiaTop indication · 109 prescription drugs

Showing 1–9 of 12 drugs

Sort

ADENOSINE

ADENOSINE · PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

SAGENT PHARMACE

ADENOSINE

ADENOSINE · PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

BEDFORD LABS

ADENOSINE

ADENOSINE · MYOCARDIAL PERFUSION IMAGE, ADJUNCT

MYLAN INSTITUTI

ADENOSINE

ADENOSINE · PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

MYLAN INSTITUTI

ADENOSINE

ADENOSINE · MYOCARDIAL PERFUSION IMAGE, ADJUNCT

EUGIA US LLC

ADENOSINE

ADENOSINE · MYOCARDIAL PERFUSION IMAGE, ADJUNCT

FRESENIUS KABI

ADENOSINE

ADENOSINE · PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

FRESENIUS KABI

ADENOSINE (DIAGNOSTIC) (adenosine)

ADENOSINE · MYOCARDIAL PERFUSION IMAGE, ADJUNCT

MYLAN INST-NOVA

ADENOSINE

ADENOSINE · MYOCARDIAL PERFUSION IMAGE, ADJUNCT

NORTHSTAR RX LL

Filter & compare in the drug finder → Opens the drug finder with Adenosine preselected. Add indication or manufacturer filters there.

About Adenosine.

Adenosine is a specific active drug moiety and endogenous purine nucleoside rather than an independent therapeutic drug class; in regulatory and pharmacological classification systems such as the FDA Established Pharmacologic Class index, it is categorized as an adenosine receptor agonist and classified clinically among miscellaneous antiarrhythmics.

Pharmacologically, it stimulates cardiac A1 adenosine receptors to inhibit adenylate cyclase, slow atrioventricular nodal conduction time, and disrupt nodal re-entrant pathways, while also activating vascular A2A receptors to produce potent coronary vasodilation.

Therapeutically, it is indicated for the acute conversion of paroxysmal supraventricular tachycardia to normal sinus rhythm and as a pharmacologic stressor during myocardial perfusion imaging to assess coronary artery disease.

fda.gov
Adenosine is a specific active drug moiety and endogenous purine nucleoside rather than an independent therapeutic drug class; in regulatory and pharmacological classification systems such as the FDA Established Pharmacologic Class index, it is categorized as an adenosine receptor agonist and classified clinically among miscellaneous antiarrhythmics
fda.gov
Adenosine is a specific active drug moiety and endogenous purine nucleoside rather than an independent therapeutic drug class; in regulatory and pharmacological classification systems such as the FDA Established Pharmacologic Class index, it is categorized as an adenosine receptor agonist and classified clinically among miscellaneous antiarrhythmics
ndclist.com
Adenosine is a specific active drug moiety and endogenous purine nucleoside rather than an independent therapeutic drug class; in regulatory and pharmacological classification systems such as the FDA Established Pharmacologic Class index, it is categorized as an adenosine receptor agonist and classified clinically among miscellaneous antiarrhythmics
fda.gov
Pharmacologically, it stimulates cardiac A1 adenosine receptors to inhibit adenylate cyclase, slow atrioventricular nodal conduction time, and disrupt nodal re-entrant pathways, while also activating vascular A2A receptors to produce potent coronary vasodilation Therapeutically, it is indicated for the acute conversion of paroxysmal supraventricular tachycardia to normal sinus rhythm and as a pharmacologic stressor during myocardial perfusion imaging to assess coronary artery disease
fda.gov
Pharmacologically, it stimulates cardiac A1 adenosine receptors to inhibit adenylate cyclase, slow atrioventricular nodal conduction time, and disrupt nodal re-entrant pathways, while also activating vascular A2A receptors to produce potent coronary vasodilation
nih.gov
Pharmacologically, it stimulates cardiac A1 adenosine receptors to inhibit adenylate cyclase, slow atrioventricular nodal conduction time, and disrupt nodal re-entrant pathways, while also activating vascular A2A receptors to produce potent coronary vasodilation
fda.gov
Therapeutically, it is indicated for the acute conversion of paroxysmal supraventricular tachycardia to normal sinus rhythm and as a pharmacologic stressor during myocardial perfusion imaging to assess coronary artery disease